On February 5th, Jinshi Data reported that Novo Nordisk (NVO.N) stated on Wednesday that its new trial of the next generation obesity drug CagriSema will focus on dose escalation and the duration of the trial to further demonstrate the potential of the drug. In December of last year, the data of the drug disappointed the market, causing the company's stock price to fall by 27%, which was one of the largest single-day declines for a European company. The CEO, Jorgensen, said that the company has confidence in the biological characteristics of this drug and is encouraged by what they see in the data.
View Original
This page may contain third-party content, which is provided for information purposes only (not representations/warranties) and should not be considered as an endorsement of its views by Gate, nor as financial or professional advice. See Disclaimer for details.
Research on the weight loss drug CagriSema by Noor and Noord
On February 5th, Jinshi Data reported that Novo Nordisk (NVO.N) stated on Wednesday that its new trial of the next generation obesity drug CagriSema will focus on dose escalation and the duration of the trial to further demonstrate the potential of the drug. In December of last year, the data of the drug disappointed the market, causing the company's stock price to fall by 27%, which was one of the largest single-day declines for a European company. The CEO, Jorgensen, said that the company has confidence in the biological characteristics of this drug and is encouraged by what they see in the data.